STOCK TITAN

[Form 4] Kewaunee Scientific Corp Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Kewaunee Scientific Corp. (KEQU) – Form 4 filed 07/28/2025 reports two open-market sales by CFO Donald T. Gardner III on 07/24/2025.

  • Sold 2,096 common shares at a weighted avg. $58.34 (range $58.00-$58.97).
  • Sold 904 common shares at a weighted avg. $59.18 (range $59.00-$59.45).
  • Total shares sold: 3,000; estimated proceeds ≈ $175k.
  • Direct ownership dropped from 17,564 to 14,564 shares, a reduction of roughly 17%.

No derivative transactions were reported and the filing offers no commentary on the purpose of the sales.

Kewaunee Scientific Corp. (KEQU) – Modulo 4 presentato il 28/07/2025 riporta due vendite sul mercato aperto effettuate dal CFO Donald T. Gardner III il 24/07/2025.

  • Vendute 2.096 azioni ordinarie a un prezzo medio ponderato di 58,34 $ (intervallo 58,00-58,97 $).
  • Vendute 904 azioni ordinarie a un prezzo medio ponderato di 59,18 $ (intervallo 59,00-59,45 $).
  • Totale azioni vendute: 3.000; ricavi stimati ≈ 175.000 $.
  • La proprietà diretta è scesa da 17.564 a 14.564 azioni, una riduzione di circa il 17%.

Non sono state segnalate transazioni derivati e il documento non offre commenti sul motivo delle vendite.

Kewaunee Scientific Corp. (KEQU) – Formulario 4 presentado el 28/07/2025 informa sobre dos ventas en el mercado abierto realizadas por el CFO Donald T. Gardner III el 24/07/2025.

  • Se vendieron 2.096 acciones ordinarias a un precio promedio ponderado de 58,34 $ (rango 58,00-58,97 $).
  • Se vendieron 904 acciones ordinarias a un precio promedio ponderado de 59,18 $ (rango 59,00-59,45 $).
  • Total de acciones vendidas: 3.000; ingresos estimados ≈ 175.000 $.
  • La propiedad directa disminuyó de 17.564 a 14.564 acciones, una reducción de aproximadamente el 17%.

No se reportaron transacciones de derivados y el formulario no ofrece comentarios sobre el propósito de las ventas.

Kewaunee Scientific Corp. (KEQU) – Form 4가 2025년 7월 28일 제출되었으며, CFO Donald T. Gardner III가 2025년 7월 24일에 두 차례의 공개시장 매도를 보고했습니다.

  • 2,096주 보통주를 가중 평균 가격 $58.34(범위 $58.00-$58.97)에 매도함.
  • 904주 보통주를 가중 평균 가격 $59.18(범위 $59.00-$59.45)에 매도함.
  • 총 매도 주식 수: 3,000주; 추정 수익 약 $175,000.
  • 직접 소유 주식 수가 17,564주에서 14,564주로 약 17% 감소함.

파생상품 거래는 보고되지 않았으며, 제출 문서에는 매도 목적에 대한 언급이 없습니다.

Kewaunee Scientific Corp. (KEQU) – Formulaire 4 déposé le 28/07/2025 rapporte deux ventes sur le marché libre effectuées par le CFO Donald T. Gardner III le 24/07/2025.

  • Vente de 2 096 actions ordinaires à un prix moyen pondéré de 58,34 $ (plage 58,00-58,97 $).
  • Vente de 904 actions ordinaires à un prix moyen pondéré de 59,18 $ (plage 59,00-59,45 $).
  • Total des actions vendues : 3 000 ; produit estimé ≈ 175 000 $.
  • La propriété directe est passée de 17 564 à 14 564 actions, soit une réduction d’environ 17 %.

Aucune transaction sur dérivés n’a été déclarée et le dépôt ne fournit aucun commentaire sur l’objectif des ventes.

Kewaunee Scientific Corp. (KEQU) – Formular 4 eingereicht am 28.07.2025 berichtet über zwei Verkäufe am offenen Markt durch CFO Donald T. Gardner III am 24.07.2025.

  • Verkauf von 2.096 Stammaktien zu einem gewichteten Durchschnittspreis von 58,34 $ (Spanne 58,00–58,97 $).
  • Verkauf von 904 Stammaktien zu einem gewichteten Durchschnittspreis von 59,18 $ (Spanne 59,00–59,45 $).
  • Gesamtverkaufte Aktien: 3.000; geschätzter Erlös ≈ 175.000 $.
  • Direktbesitz sank von 17.564 auf 14.564 Aktien, eine Reduktion von etwa 17 %.

Keine Derivatgeschäfte wurden gemeldet und die Einreichung enthält keine Angaben zum Zweck der Verkäufe.

Positive
  • None.
Negative
  • CFO reduced direct shareholding by approximately 17% through open-market sales of 3,000 shares
  • Filing provides no explanation for the insider’s decision to sell, leaving motives unclear

Insights

CFO’s 3,000-share sale signals potential caution; magnitude modest but timing near $59 raises sentiment questions.

The transaction trims the CFO’s stake by ~17%, yielding about $175k. Insider sales from key executives often create negative sentiment, particularly for thin-float stocks such as KEQU. Absence of option exercise or stated diversification motive limits benign interpretations. While ownership remains at 14,564 shares, the reduced alignment could prompt short-term pressure and warrants monitoring of future insider activity.

Executive sale modest in size but transparency limited; governance impact marginal.

Gardner disclosed the weighted-average price ranges as required, yet provided no narrative context. The lack of complementary derivative activity suggests a straightforward cash sale. From a governance standpoint, the sale is within reporting norms, but investors will note the reduced equity stake when assessing management alignment with shareholder interests.

Kewaunee Scientific Corp. (KEQU) – Modulo 4 presentato il 28/07/2025 riporta due vendite sul mercato aperto effettuate dal CFO Donald T. Gardner III il 24/07/2025.

  • Vendute 2.096 azioni ordinarie a un prezzo medio ponderato di 58,34 $ (intervallo 58,00-58,97 $).
  • Vendute 904 azioni ordinarie a un prezzo medio ponderato di 59,18 $ (intervallo 59,00-59,45 $).
  • Totale azioni vendute: 3.000; ricavi stimati ≈ 175.000 $.
  • La proprietà diretta è scesa da 17.564 a 14.564 azioni, una riduzione di circa il 17%.

Non sono state segnalate transazioni derivati e il documento non offre commenti sul motivo delle vendite.

Kewaunee Scientific Corp. (KEQU) – Formulario 4 presentado el 28/07/2025 informa sobre dos ventas en el mercado abierto realizadas por el CFO Donald T. Gardner III el 24/07/2025.

  • Se vendieron 2.096 acciones ordinarias a un precio promedio ponderado de 58,34 $ (rango 58,00-58,97 $).
  • Se vendieron 904 acciones ordinarias a un precio promedio ponderado de 59,18 $ (rango 59,00-59,45 $).
  • Total de acciones vendidas: 3.000; ingresos estimados ≈ 175.000 $.
  • La propiedad directa disminuyó de 17.564 a 14.564 acciones, una reducción de aproximadamente el 17%.

No se reportaron transacciones de derivados y el formulario no ofrece comentarios sobre el propósito de las ventas.

Kewaunee Scientific Corp. (KEQU) – Form 4가 2025년 7월 28일 제출되었으며, CFO Donald T. Gardner III가 2025년 7월 24일에 두 차례의 공개시장 매도를 보고했습니다.

  • 2,096주 보통주를 가중 평균 가격 $58.34(범위 $58.00-$58.97)에 매도함.
  • 904주 보통주를 가중 평균 가격 $59.18(범위 $59.00-$59.45)에 매도함.
  • 총 매도 주식 수: 3,000주; 추정 수익 약 $175,000.
  • 직접 소유 주식 수가 17,564주에서 14,564주로 약 17% 감소함.

파생상품 거래는 보고되지 않았으며, 제출 문서에는 매도 목적에 대한 언급이 없습니다.

Kewaunee Scientific Corp. (KEQU) – Formulaire 4 déposé le 28/07/2025 rapporte deux ventes sur le marché libre effectuées par le CFO Donald T. Gardner III le 24/07/2025.

  • Vente de 2 096 actions ordinaires à un prix moyen pondéré de 58,34 $ (plage 58,00-58,97 $).
  • Vente de 904 actions ordinaires à un prix moyen pondéré de 59,18 $ (plage 59,00-59,45 $).
  • Total des actions vendues : 3 000 ; produit estimé ≈ 175 000 $.
  • La propriété directe est passée de 17 564 à 14 564 actions, soit une réduction d’environ 17 %.

Aucune transaction sur dérivés n’a été déclarée et le dépôt ne fournit aucun commentaire sur l’objectif des ventes.

Kewaunee Scientific Corp. (KEQU) – Formular 4 eingereicht am 28.07.2025 berichtet über zwei Verkäufe am offenen Markt durch CFO Donald T. Gardner III am 24.07.2025.

  • Verkauf von 2.096 Stammaktien zu einem gewichteten Durchschnittspreis von 58,34 $ (Spanne 58,00–58,97 $).
  • Verkauf von 904 Stammaktien zu einem gewichteten Durchschnittspreis von 59,18 $ (Spanne 59,00–59,45 $).
  • Gesamtverkaufte Aktien: 3.000; geschätzter Erlös ≈ 175.000 $.
  • Direktbesitz sank von 17.564 auf 14.564 Aktien, eine Reduktion von etwa 17 %.

Keine Derivatgeschäfte wurden gemeldet und die Einreichung enthält keine Angaben zum Zweck der Verkäufe.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Gardner Donald T. III

(Last) (First) (Middle)
2700 WEST FRONT STREET

(Street)
STATESVILLE NC 28677

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KEWAUNEE SCIENTIFIC CORP /DE/ [ KEQU ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/24/2025 S 2,096 D $58.34(1) 15,468 D
Common Stock 07/24/2025 S 904 D $59.18(2) 14,564 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.97 inclusive. The reporting person undertakes to provide Kewaunee Scientific Corporation ("Kewaunee"), any security holder of Kewaunee, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.45 inclusive. The reporting person undertakes to provide Kewaunee Scientific Corporation ("Kewaunee"), any security holder of Kewaunee, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Remarks:
/s/ Donald T. Gardner III 07/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many KEQU shares did the CFO sell on 07/24/2025?

The filing shows sales of 3,000 common shares across two transactions.

At what prices were the KEQU shares sold?

Weighted-average prices were $58.34 (range $58.00-$58.97) for 2,096 shares and $59.18 (range $59.00-$59.45) for 904 shares.

How many KEQU shares does the CFO now own?

After the transactions, Donald T. Gardner III directly owns 14,564 shares.

Did the insider report any derivative security transactions?

No; Table II contains no derivative transactions.

What percentage of the CFO’s previous holdings was sold?

Based on the filing data, the sale represents roughly 17% of his prior direct holdings.
Kewaunee Scienti

NASDAQ:KEQU

KEQU Rankings

KEQU Latest News

KEQU Latest SEC Filings

KEQU Stock Data

165.48M
2.21M
24.44%
44.44%
1.62%
Furnishings, Fixtures & Appliances
Laboratory Apparatus & Furniture
Link
United States
STATESVILLE